US$ 21.02
bpc-157 oral vs injectable bioavailability study Explained: Benefits, Safety & Options BPC-157 Oral vs Injection: Bioavailability
Description
Journal of cellular and molecular medicine, 25(17), 82228228
Areas requiring further investigation include: Tissue-specific dose optimisation: While 10-20 g/kg appears broadly effective across various tissues, whether specific tissues (cartilage versus muscle versus nerve) respond optimally to different doses has not been systematically explored

However, the lack of extensive human clinical trials means long-term safety data in humans remains limited

This injection is made by Dr Reddys Laboratories Ltd which follows all the international standards for manufacturing its products
